Elias Papadimas - Exicure CFO Sec
| XCUR Stock | USD 29.49 2.50 7.81% |
Insider
Elias Papadimas is CFO Sec of Exicure
| Age | 48 |
| Address | 2430 North Halsted Street, Chicago, IL, United States, 60614 |
| Phone | 847 673 1700 |
| Web | https://www.exicuretx.com |
Exicure Management Efficiency
The company has return on total asset (ROA) of (0.2641) % which means that it has lost $0.2641 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4441) %, meaning that it created substantial loss on money invested by shareholders. Exicure's management efficiency ratios could be used to measure how well Exicure manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/30/2024, Return On Tangible Assets is likely to grow to -1.39. In addition to that, Return On Capital Employed is likely to drop to -1.74. At this time, Exicure's Net Tangible Assets are relatively stable compared to the past year. As of 11/30/2024, Non Currrent Assets Other is likely to grow to about 3.1 M, while Non Current Assets Total are likely to drop slightly above 7.8 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| David Mack | Pmv Pharmaceuticals | 62 | |
| Deepika PharmD | Pmv Pharmaceuticals | 47 | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| Philippe MBA | Milestone Pharmaceuticals | 62 | |
| Robert Westwood | Cyclacel Pharmaceuticals | 80 | |
| Anne Moon | Tempest Therapeutics | N/A | |
| FACC MD | Milestone Pharmaceuticals | 60 | |
| Dominic Cundari | DiaMedica Therapeutics | 73 | |
| Dr Dubensky | Tempest Therapeutics | 66 | |
| BBA CPA | Lumos Pharma | 57 | |
| David Lovejoy | Protagenic Therapeutics | N/A | |
| Evan Hecker | Ikena Oncology | N/A | |
| Timothy CPA | Imunon Inc | 66 | |
| Lori CPA | Lumos Pharma | 40 | |
| Jennifer Schroeder | Ikena Oncology | N/A | |
| FACC FAHA | Milestone Pharmaceuticals | 66 | |
| Thomas Shenk | Pmv Pharmaceuticals | 77 | |
| Grey Wilkinson | Oncolytics Biotech | N/A | |
| Carl Langren | Lumos Pharma | 69 | |
| Leila MD | Pmv Pharmaceuticals | 61 | |
| Edward Calamai | DiaMedica Therapeutics | N/A | |
Management Performance
| Return On Equity | -1.44 | ||||
| Return On Asset | -0.26 |
Exicure Leadership Team
Elected by the shareholders, the Exicure's board of directors comprises two types of representatives: Exicure inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Exicure. The board's role is to monitor Exicure's management team and ensure that shareholders' interests are well served. Exicure's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Exicure's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jiyoung Hwang, Secretary CFO | ||
| Paul Kang, President CEO | ||
| Matthias Schroff, Pres CEO | ||
| Bart Anderson, Director RD | ||
| Sarah Longoria, Chief Officer | ||
| Joshua Miller, Chief Officer | ||
| Elias Papadimas, CFO Sec |
Exicure Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Exicure a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.44 | ||||
| Return On Asset | -0.26 | ||||
| Operating Margin | (11.93) % | ||||
| Current Valuation | 75.28 M | ||||
| Shares Outstanding | 2.17 M | ||||
| Shares Owned By Insiders | 46.70 % | ||||
| Shares Owned By Institutions | 4.28 % | ||||
| Number Of Shares Shorted | 16.15 K | ||||
| Price To Book | 44.98 X | ||||
| Price To Sales | 128.12 X |
Pair Trading with Exicure
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Exicure position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Exicure will appreciate offsetting losses from the drop in the long position's value.Moving together with Exicure Stock
Moving against Exicure Stock
| 0.59 | RDY | Dr Reddys Laboratories | PairCorr |
| 0.52 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.51 | LLY | Eli Lilly | PairCorr |
| 0.51 | TAK | Takeda Pharmaceutical | PairCorr |
| 0.43 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
The ability to find closely correlated positions to Exicure could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Exicure when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Exicure - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Exicure to buy it.
The correlation of Exicure is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Exicure moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Exicure moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Exicure can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Exicure Stock Analysis
When running Exicure's price analysis, check to measure Exicure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Exicure is operating at the current time. Most of Exicure's value examination focuses on studying past and present price action to predict the probability of Exicure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Exicure's price. Additionally, you may evaluate how the addition of Exicure to your portfolios can decrease your overall portfolio volatility.